“And we talked about shifting at least 30% to 40% of the total U.S. Opdivo business, we can do that ahead of the LOE, which is in late 2028.”

In context

“ve here? Chris Boerner: So do you mind repeating the second question? Akash Tewari: In terms of protections around subcu Opdivo in terms of the length of duration versus what Merck is communicating on subcu KEYTRUDA? Chris Boerner: Got it. Sorry, we just missed that. So with respect to J&J, no change in our partnership with J&J. J&J has communicated, they continue to be squarely supportive and engaged on the Milvexian program. And in fact, their work on the ongoing Phase 3 programs continues to be very, very good, and we've got a very good relationship with J&J on that program. And then Adam, I'll ask you to take the second. Adam Lenkowsky: Yes. Regarding the subcu. First, we look forward to the PDUFA date for the nivolumab subcu in late December. Launch planning is progressing very well. And we talked about shifting at least 30% to 40% of the total U.S. Opdivo business, we can do that ahead of the LOE, which is in late 2028. As far as the extension of the I-O franchise. This is what excites us potentially about this product because not only does subcu address the treatment burden for patients and physicians with a 3- to 5-minute fusion time as well as in opposite injection what this is going to do based on the broad patent state for the subcu, it will allow us to extend our franchise into the next decade. Operator: Next question will come from James Shin with Deutsche Bank. James Shin: I just want to go back to Milvexian real quick. I really appreciate the update on the stroke and embolism event rates. But was there any separation between the arms? And perhaps even more importantly, do you have any color on bleed rates. Samit Hirawat: Thank you, James, for the question. Obviously, we can't look at those from”